JP2023552554A - フィツシランを用いた血友病の処置 - Google Patents
フィツシランを用いた血友病の処置 Download PDFInfo
- Publication number
- JP2023552554A JP2023552554A JP2023534111A JP2023534111A JP2023552554A JP 2023552554 A JP2023552554 A JP 2023552554A JP 2023534111 A JP2023534111 A JP 2023534111A JP 2023534111 A JP2023534111 A JP 2023534111A JP 2023552554 A JP2023552554 A JP 2023552554A
- Authority
- JP
- Japan
- Prior art keywords
- fitusiran
- patient
- patients
- subcutaneously
- levels
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
- G01N2333/8121—Serpins
- G01N2333/8128—Antithrombin III
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/224—Haemostasis or coagulation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063121973P | 2020-12-06 | 2020-12-06 | |
| US63/121,973 | 2020-12-06 | ||
| US202163272629P | 2021-10-27 | 2021-10-27 | |
| US63/272,629 | 2021-10-27 | ||
| US202163275344P | 2021-11-03 | 2021-11-03 | |
| US63/275,344 | 2021-11-03 | ||
| PCT/US2021/062078 WO2022120292A1 (en) | 2020-12-06 | 2021-12-06 | Treatment of hemophilia with fitusiran |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023552554A true JP2023552554A (ja) | 2023-12-18 |
| JP2023552554A5 JP2023552554A5 (cg-RX-API-DMAC7.html) | 2024-12-13 |
Family
ID=80112089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023534111A Pending JP2023552554A (ja) | 2020-12-06 | 2021-12-06 | フィツシランを用いた血友病の処置 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240027478A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4255566A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023552554A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230117403A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021391951A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3204344A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL303452A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023006651A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202237151A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022120292A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3258425A1 (en) * | 2022-06-08 | 2023-12-14 | Genzyme Corporation | Treatment of hemophilia with fitusiran in pediatric patients |
| EP4612687A1 (en) | 2022-11-02 | 2025-09-10 | Genzyme Corporation | Systems and methods for modeling thrombin-antithrombin |
| TW202525306A (zh) * | 2023-09-15 | 2025-07-01 | 美商健臻公司 | 用非妥西蘭(fitusiran)治療a型血友病 |
| WO2025171279A1 (en) * | 2024-02-09 | 2025-08-14 | Genzyme Corporation | Treatment of hemophilia with fitusiran |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200163987A1 (en) * | 2017-07-10 | 2020-05-28 | Genzyme Corporation | Methods and compositions for treating a bleeding event in a subject having hemophilia |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| IL308717A (en) | 2015-12-07 | 2024-01-01 | Genzyme Corp | Methods and compositions for treating a serpinc1-associated disorder |
-
2021
- 2021-12-06 KR KR1020237022579A patent/KR20230117403A/ko active Pending
- 2021-12-06 TW TW110145480A patent/TW202237151A/zh unknown
- 2021-12-06 IL IL303452A patent/IL303452A/en unknown
- 2021-12-06 WO PCT/US2021/062078 patent/WO2022120292A1/en not_active Ceased
- 2021-12-06 US US18/256,199 patent/US20240027478A1/en active Pending
- 2021-12-06 EP EP21841061.1A patent/EP4255566A1/en active Pending
- 2021-12-06 JP JP2023534111A patent/JP2023552554A/ja active Pending
- 2021-12-06 CA CA3204344A patent/CA3204344A1/en active Pending
- 2021-12-06 MX MX2023006651A patent/MX2023006651A/es unknown
- 2021-12-06 AU AU2021391951A patent/AU2021391951A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200163987A1 (en) * | 2017-07-10 | 2020-05-28 | Genzyme Corporation | Methods and compositions for treating a bleeding event in a subject having hemophilia |
Non-Patent Citations (5)
| Title |
|---|
| "Alnylam Initiates Fitusiran (ALN-AT3) Dosing on Hemophilia A and B Patients with Inhibitors in Ongoi", ALNYLAM PHARMACEUTICAL PRESS RELEASE, [ONLINE], JPN6026004829, 14 May 2016 (2016-05-14), ISSN: 0005793283 * |
| BHAGUNDE P; ET AL: "PB0526 / FITUSIRAN POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC (POPPK/PD) MODELING 以下備考", RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS - ABSTRACTS OF THE 64TH ANNUAL MEETING 以下省略, vol. VOL.5, NR.S2, JPN5024006870, October 2021 (2021-10-01), GB, pages 399 - 400, ISSN: 0005793285 * |
| NATURE MEDICINE, vol. 21, no. 5, JPN6026004828, 2015, pages 492 - 497, ISSN: 0005793282 * |
| PASI K J; ET AL: "TARGETING OF ANTITHROMBIN IN HEMOPHILIA A OR B WITH RNAI THERAPY", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. VOL.377, NR.9, JPN5024006869, 10 July 2017 (2017-07-10), pages 819 - 828, ISSN: 0005793281 * |
| SRIDHARAN G; ET AL: "P093 / MODELING THE IMPACT OF FACTOR ADMINISTRATION AND ANTITHROMBIN LEVEL ON THROMBIN GENERATION", HAEMOPHILIA, vol. 24, JPN5024006868, February 2018 (2018-02-01), GB, pages 75 - 76, ISSN: 0005793284 * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202237151A (zh) | 2022-10-01 |
| EP4255566A1 (en) | 2023-10-11 |
| US20240027478A1 (en) | 2024-01-25 |
| AU2021391951A1 (en) | 2023-07-20 |
| IL303452A (en) | 2023-08-01 |
| KR20230117403A (ko) | 2023-08-08 |
| AU2021391951A9 (en) | 2024-05-02 |
| MX2023006651A (es) | 2023-08-02 |
| WO2022120292A1 (en) | 2022-06-09 |
| CA3204344A1 (en) | 2022-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20230117403A (ko) | 피투시란을 이용한 혈우병의 치료 | |
| WO2022120291A1 (en) | Treatment of hemophilia with fitusiran | |
| JP2023531679A (ja) | 血友病を処置するための方法および組成物 | |
| JP2025519491A (ja) | 小児患者における血友病a及びbの処置のためのフィツシラン | |
| US20240000744A1 (en) | Treatment of Hemophilia with Fitusiran | |
| US20210187083A1 (en) | Modified factor vii polypeptides for subcutaneous administration and on-demand treatment | |
| TW202525306A (zh) | 用非妥西蘭(fitusiran)治療a型血友病 | |
| JP2025500412A (ja) | 血友病患者において患者報告アウトカムを改善するのに使用するためのフィツシラン | |
| CN116635040A (zh) | 用非妥西兰治疗血友病 | |
| TW202237149A (zh) | 用於治療出血性障礙之組成物及方法 | |
| EP3581196A1 (de) | Inhibitoren des transferrinrezeptor-2 zur verwendung bei der behandlung von erkrankungen des knochens, des eisenstoffswechsels und der blutbildung | |
| HK40056298A (en) | Modified factor vii polypeptides for subcutaneous administration | |
| HK40056298B (en) | Modified factor vii polypeptides for subcutaneous administration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241205 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241205 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260210 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260501 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260810 |